Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

News
Monday, August 31, 2020   (0 Comments - view/add)
ITOG's Collaborative Research Leading to Major Breakthrough in Treatment of Thyroid Cancer »
It is with great pleasure to share that Dr. Lori Wirth, Dr. Eric Sherman, Dr. Bruce Robinson et al. (NEJM, Aug 27 2020) fo...
Monday, August 31, 2020   (0 Comments - view/add)
Dr. Robert Gagel Receives Jean Vicks Inspiration Award »
During the ITOG General Membership meeting on July 30 th , 2020, the Board of Directors was pleased to present Dr. Rob...
Friday, August 28, 2020   (0 Comments - view/add)
ITOG Board of Directors, Member-At-Large Election Results »
We are pleased to announce the ITOG Board of Directors, Member-At-Large Election Results  Elected BOD  Term:...
Tuesday, October 6, 2020   (0 Comments - view/add)
ITOG Board of Directors Vote to Move Forward on Tumor Registry Partnership and Development »
A strength of ITOG is its multidisciplinary team members’ routine care of patients with advanced and rare malignancies. Ga...
Wednesday, May 20, 2020   (1 Comment - view/add)
ITOG Quarterly Newsletter June 2020 »
ITOG Quarterly Newsletter June 2020  j...
Friday, May 15, 2020   (0 Comments - view/add)
ACCRU-ITOG-1504 Achieves Accrual Goal »
  Congratulations  to  Principal Investigator:  Bryan Haugen  at  The  Univers...
Tuesday, May 12, 2020   (0 Comments - view/add)
FDA Approval for Retevmo (selpercatinib) »
Based on the clinical trial results from the LIBRETTO-001 ( NCT03157128 ) Phase 1/2 trial in RET -altered thyroid cance...
Monday, April 6, 2020   (0 Comments - view/add)
ITOG Robert F. Gagel Discovery Award Recipient Carmelo Nucera, MD »
Please join us in congratulating  the 2019 Robert F. Gagel ITOG Discovery Award  Recipient,  Carmelo Nucera...
Monday, April 6, 2020   (0 Comments - view/add)
LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer »
ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medica...
Monday, April 6, 2020   (0 Comments - view/add)
ITOG Selumetinib Trial Achieves Accrual Goal! »
ITOG Selumetinib Trial Achieves Accrual Goal! Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloa...
Friday, October 11, 2019   (0 Comments - view/add)
ITOG Board of Directors Announces a New International Board Member »
ITOG is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Boa...

Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495

614-293-9779

Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.